Drug Development Pipeline
Back to the Drug Development Pipeline
Alpha 1 Anti-Trypsin
Alpha 1 Anti-trypsin is an aerosolized protease inhibitor with anti-inflammatory properties, derived from human plasma.
A Phase 2 trial was completed in the U.S. No further clinical development in CF is planned at this time.
The program was sponsored by Grifols Therapeutics, Inc.
This therapy is no longer being pursued by Grifols Therapeutics Inc.
Recent Alpha 1 Anti-Trypsin Studies
Completed with Results
Phase 2 study of inhaled Alpha-1 HC in people with CF (Grifols T6005-201)
Sign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Explore clinical trials
Be a part of the movement transforming the future of cystic fibrosis treatment.Learn More